Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Phase 2, randomized, open-label study to evaluate the safety and efficacy of maraviroc,
favipiravir, and both drugs administered along with currently used therapy in hospitalized
patients with pulmonary SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)
infection (COVID-19)
Phase:
Phase 2
Details
Lead Sponsor:
Hospital General de México Dr. Eduardo Liceaga
Collaborators:
CCINSHAE. Secretaría de Salud. México Centro de Investigación en. Enfermedades Infecciosas, Mexico Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran